Center for Regenerative Medicine, The Abigail Wexner Research Institute, Nationwide Childrens Hospital, Columbus, OH, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
Center for Regenerative Medicine, The Abigail Wexner Research Institute, Nationwide Childrens Hospital, Columbus, OH, USA; Biomedical Sciences Graduate Program, The Ohio State University College of Medicine, Columbus, OH, USA.
Semin Fetal Neonatal Med. 2022 Feb;27(1):101225. doi: 10.1016/j.siny.2021.101225. Epub 2021 Feb 27.
Congenital heart disease (CHD) represents a large clinical burden, representing the most common cause of birth defect-related death in the newborn. The mainstay of treatment for CHD remains palliative surgery using prosthetic vascular grafts and valves. These devices have limited effectiveness in pediatric patients due to thrombosis, infection, limited endothelialization, and a lack of growth potential. Tissue engineering has shown promise in providing new solutions for pediatric CHD patients through the development of tissue engineered vascular grafts, heart patches, and heart valves. In this review, we examine the current surgical treatments for congenital heart disease and the research being conducted to create tissue engineered products for these patients. While much research remains to be done before tissue engineering becomes a mainstay of clinical treatment for CHD patients, developments have been progressing rapidly towards translation of tissue engineering devices to the clinic.
先天性心脏病（CHD）是一个巨大的临床负担，是新生儿中与先天缺陷相关的死亡的主要原因。CHD 的主要治疗方法仍然是使用人造血管移植物和瓣膜进行姑息性手术。由于血栓形成、感染、内皮化有限以及缺乏生长潜力，这些设备在儿科患者中的效果有限。组织工程学通过开发组织工程血管移植物、心脏贴片和心脏瓣膜，为儿科 CHD 患者提供了新的解决方案，显示出了希望。在这篇综述中，我们研究了先天性心脏病的当前手术治疗方法，以及为这些患者开发组织工程产品的研究进展。尽管在组织工程学成为 CHD 患者临床治疗的主要方法之前还有很多研究工作要做，但组织工程学设备向临床的转化进展迅速。
